Member Info for Balerno2

Ok so I was looking at the main tranche when they came in at 5p plus the loan notes.

Who’s to object to £2 then?

The funds such as Remile etc look for an exit of 20x what they pitched in at so that’s £1 or £1.2bn in real money.

LF wants her £40m for trials on scib1 so this has to be heading for 60p in the summer. They also need to pay off the loan notes by 2025 or RM will have over 30% meaning an offer for the firm.

How old is LD and when will she want to smell the roses?

Like everything sclp it’s slowly coming to a conclusion. Thank goodness!

Thanks WTP and hopefully TF is right in expecting another RNS.

So is the the first time that they have overtly directed Enquiries to commercial enquiries.? Begs the question is this one of the antibodies with existing interest or not? Given the short notice of the presentation, is this being used to ramp up negotiations?

Again more evidence of an improved commercial negotiation IMHO.

Hi TF,

Trouble is big Pharma has the personalised vaccine results now as opposed to us working up the data. So tomorrow’s conference may be another stone in the wall in building the alternative case. So maybe another RNS tomorrow?

Ho ho ho! Somehow that wasn’t in the JD. So how can you be head of finance without a number 2 who does the numbers and is more of an anorak?

Wheelers and dealers usually aren’t anoraks.

When you have to divide by 1.2 bn you need a large calculator.

So it’s been placed into administration. It’s not a liquidation so there may be a prepack or the components will be sold off. There is a factory plus the IP. Watch this space for redundancy announcements. Given the precarious nature of the finances then these are the options where the vultures can get cheap pickings. Hope we get the forms from the administrators soon.

Really sorry to hear about the King’s cancer. No doubt he’ll get the best of treatment. Of course we don’t know the type yet and no doubt his treatment plan is already settled by his clinicians. The big boys will be banging at the door but I wonder if and what immunotherapy will be advised?

So Seth thinks he can get £6m ish per mab on a non exclusive basis. Someone will have to go much higher for exclusivity but beware the tail which comes alongside. Many firms may notwant to play for the other assets if x is attached.

Chances are there will be a stand off until they also decide to partner on sclp or modi. Then maybe an entire bid.

As usual, this webcast just goes into a loop and doesn’t get me in. Tried to contact the techies but no success.

Enjoy yourselves guys.

Surely if you are going to go for a £30-&40m fundraise to get the new scib trial off the ground , then you will need to get the mood music right and sell the sizzle in advance. That implies an optimistic investor presentation plus enough good news to raise the share price.

It also means confidence through improved communications, technical excellence, new data and results.

Why go for the funding if the products aren’t working?

Hi Burble,

That is a simple and brilliant explanation of their mechanisms. I congratulate you on that. Maybe you should send it the sclp’s comms people?

It is in line with the Liverpool prof and the Texas institute.

This shows the power of communications and your genius in being able to simplify powerful concepts.

Brilliant.

Hi TF

Well interim results were on 25 th and 26th Jan for the last 2 years respectively. Hoping for an RNS tomorrow or Thursday. It’s been quiet re MODI1 so maybe some news will be forthcoming. After all didn’t LD promise an investor briefing in the new year?

So violin,

I seem to recall the CLNs are redeemed next year. All within the timescale of the £30/60m fundraise. If they are redeemed doesn’t that give Redmile a >30% stake so meaning a bid. Would they do that or just accept pay back? Probably it’s a payback with a new funding round at a higher SP. Given their holding it’s a win -win.

Provided the subsequent data is as good as we expect. However I don’t think the BOD are running a con trick and Lindy does need to smell the roses for all her hard work.

Maybe finally this year is pivotal?

Listing on Nasdaq has to be done with a higher share price then doesn’t it? So would that mean a consolidation?

The first one is Invus. Do you think this investment meets their profiles?

"We talked to CEO Lindy Durrant on 20 December. The offering brought in three new institutional investors (two VCs with life science expertise, Invus and Pentwater, and one mainstream firm, Platinum), and Prof Durrant said they had further potential interest for larger stakes from others."

menu

What We Look For

Transformational opportunities to create extraordinary business performance

Both the easy and the difficult answer to the question is: transformational opportunities where we can partner with owner-managers to create extraordinary business performance and enjoy the resulting financial rewards. Given this high bar and our small team, we are very selective about the companies with which we get involved. We only make a handful of new investments each year.

We are flexible in the size of equity checks we write. Our initial investments in companies have been as low as $10 million, and as high as $800 million. We invest across the full spectrum of lifecycle, from early stage growth companies

Pentwater Capital Management LP is a multi-billion-dollar global investment management firm. The Firm was founded in April 2007 under the leadership of Matthew Halbower.

Pentwater employs a bottom-up, opportunistic investment approach with a focus on event driven investing across the capital structure. Active risk management and capital preservation are key priorities. The seasoned Pentwater team enjoys a collaborative culture across the firm’s offices and strategies. In addition to our investment process, we are committed to providing investors with institutional quality client service, operations, and compliance

Not sure if this is the right one.

Platinum Capital Management Ltd. is a global investment firm that manages single-strategy funds and funds of funds for investors worldwide. Founded in 1999, Platinum Capital Management Ltd. is based in London, with affiliate offices in Isle of Man and Los Angeles.

Platinum’s expertise in the research, development and implementation of unique alternative investment products derives from the aggregate investment experience of Platinum professionals. Platinum funds offer investors a range of investment strategies built on Platinum’s commitment to delivering quality long-term investment success and a culture that embraces the continual enhancement of its investment selection, asset allocation and ongoing risk management capabilities

Hi EE

Just casting the rod with lots of bait. What sector specialists have FOMO? May as well crystallise the interest especially across multiple investors. It’s how we get the SP up and success breads success. Has anyone researched the named new investors. Are they UK, US or other?

Hi TF

Well it looks like the plan is starting with

Our CFO Sath Nirmalananthan will be attending the @JPMorgan Healthcare Conference 2024 taking place in San Francisco, CA from 8-11 Jan.

Maybe the new apppointments are changing the culture and going for it based upon undisclosed info. Not just scib1 but also modi1.

When will the markets get the hint?

Hi TF

If you’ve done a recent fundraise, why not advance while the going is good? Why not let the market know can get funding for the scib1 registration phase as it implies results are better than you said. If a partner is also in the frame surely this puts pressure on them. Cossery is a seasoned Pharma business pro. Let’s play hardball. It’s time now!